Replies to post #129851 on Biotech Values

[acgood]

Agree with you here...50/50 ownership is the baseline case, but can be interpreted in many ways.

Any way it turns out this will be an interesting case study to continue to follow. Or perhaps FDA biosimilar guidance will be published soon as anticipated, and they can simplify everything but just negotiating a buyout by NVS ;)